10568 Federal Register / Vol. 62, No. 45 / Friday, March 7, 1997 / Notices

including plants in Orangeburg and

Sumter, South Carolina, and a research

and development center in Ann Arbor,

Michigan, as well as technology outside

the United States which supports that

business. Metal Leve and Mahle will

cease to have any rights to what was

formerly the Metal Leve articulated

piston technology once the divestiture

required by the proposed Order has

been accomplished.

The proposed Order requires that the

divestiture be completed within ten

days of the Order becoming final. Thus,

the Proposed Respondents must file an

acceptable application for divestiture

well before the proposed Order is made

final, so that the application can be

placed on the public record for thirty

days, the Commission can determine

whether to approve it, and Respondents

can complete the required divestiture

within the time period set forth in the

proposed Order.

If the required divestiture is not

accomplished within ten days of the

Order being made final, then a trustee

may be appointed to divest the business.

The trustee may add some or all of the

Metal Leve, S.A. piston business to

accomplish the divestiture. This crown

jewel provision ensures that the

required divestiture will be

accomplished in a timely manner.

A Hold Separate Agreement accepted

by the Commission on August 30, 1996,

will continue in effect until the

divestiture required by the proposed

Order is accomplished. The Hold

Separate requires Metal Leve to be

operated independently of Mahle on a

worldwide basis and requires Metal

Leve, Inc. to be maintained as a viable

competitor in the business in which it

was engaged prior to Mahle’s

acquisition of Metal Leve.

Finally, the proposed Order prohibits

Mahle or Metal Leve from acquiring any

interest in any other company engaged

in the manufacture or sale of articulated

pistons in the United States, without

prior notice to the Commission, for a

period of ten (10) years.

The purpose of this analysis is to

facilitate public comment on the

proposed Order. This analysis is not

intended to constitute an official

interpretation of the Agreement or the

proposed Order or in any way to modify

the terms of the Agreement or the

proposed Order.

Donald S. Clark,

Secretary.

[FR Doc. 97–5708 Filed 3–6–97; 8:45 am]

BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Notice of Meeting of the National

Bioethics Advisory Commission

(NBAC), Genetics Subcommittee

Correction notice for previously

published notice (Published on

February 26, 1997, Page 8743, 2nd

Column). The date is corrected to read:

Date: Wednesday, March 5, 1997, 7:00

a.m. to 1:00 p.m.

FOR FURTHER INFORMATION CONTACT: Ms.

Henrietta Hyatt-Knorr, National

Bioethics Advisory Commission, MSC–

7508, 6100 Executive Boulevard, Suite

3C01, Rockville, Maryland 20892–7508,

telephone 301–402–4242, fax number

301–480–6900.

Dated: February 26, 1997.

Henrietta Hyatt-Knorr,

Acting Deputy Director, National Bioethics

Advisory Commission.

[FR Doc. 97–5690 Filed 3–4–97; 2:25 pm]

BILLING CODE 4160–17–M

Meeting of the National Bioethics

Advisory Commission (NBAC)

SUMMARY: Pursuant to section 10(d) of

the Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is given of a meeting of the National

Bioethics Advisory Commission. The

Commission members will address the

bioethical issues arising from the

research on human biology and

behavior, and in the applications of that

research including clinical. They will

also begin a review of the legal and

ethical issues associated with the recent

report of a technique of cloning sheep.

The public is invited to speak on any of

these issues and opportunities for

statements will be provided.

DATES: Thursday, March 13, 1997, 8

a.m. to 4:30 p.m., and Friday, March 14,

1997, 8 a.m. to 4:30 p.m.

LOCATION: The Commission will meet at

the Watergate Hotel, Continental

Chesapeake Extender Room, 2650

Virginia Avenue, NW, Washington, DC.

SUPPLEMENTARY INFORMATION: The

President established the National

Bioethics Advisory Commission (NBAC)

by Executive Order 12975 on October 3,

1995. The charter of the Commission

was signed on July 26, 1996. The first

meeting took place on October 4, 1996.

The mission of the NBAC is to advise

and make recommendations to the

National Science and Technology

Council and other entities on bioethical

issues arising from the research on

human biology and behavior, and in the

applications of that research. On

February 24, 1997, the President

instructed the Commission to undertake

a review of the legal and ethical issues

associated with the recent report of a

technique for cloning sheep. This

scientific discovery raises a host of

important issues including serious

ethical questions, in particular the

possible use of this technique to clone

human embryos, as well as the promise

of benefits in a number of areas.

Tentative Agenda

The Commission will 1) receive

reports from its subcommittees, 2)

discuss and plan the Commission’s 90-

day report to the President on issues of

cloning, and 3) listen to presentations

from the public.

Public Participation

The meeting is open to the public

with attendance limited by the

availability of space. Members of the

public who wish to present oral

statements should contact the Acting

Deputy Executive Director of the NBAC

by telephone, fax machine, or mail as

shown below as soon as possible, prior

to the meeting. The Chair of the NBAC

will reserve time for presentations by

persons requesting an opportunity to

speak. The order of speakers will be

assigned either on a first come, first

serve basis or along other

considerations. Individuals unable to

make oral presentations are encouraged

to mail or fax their comments to the

NBAC at least two business days prior

to the meeting for distribution to the

subcommittee members and inclusion

in the record. We urge anyone planning

to speak to call the NBAC office two or

three days before the meeting to obtain

information on the final logistical

arrangements.

Persons needing special assistance,

such as sign language interpretation or

other special accommodations, should

contact NBAC staff at the address or

telephone number listed below as soon

as possible.

FOR FURTHER INFORMATION CONTACT: Ms.

Henrietta D. Hyatt-Knorr, National

Bioethics Advisory Commission, MSC–

7508, 6100 Executive Boulevard, Suite

3C01, Rockville, Maryland 20892–7508,

telephone 301–402–4242, fax number

301–480–6900.

Dated: February 25, 1997.

Henrietta Hyatt-Knorr,

Acting Deputy Executive Director, National

Bioethics Advisory Commission.

[FR Doc. 97–5691 Filed 3–6–97; 8:45 am]

BILLING CODE 4160–17–P